Cell-free is elevated in chronic myeloproliferative neoplasms: correlation with thrombosis and disease progression

MARIN OYARZÚN CP; MOIRAGHI B; CAULA V; SACKMANN F; VALLEJOS V; MARTA RF; GUTIERREZ MI; COTRES V; GLEMBOTSKY AC; BENDEK G; GOETTE NP; SCHATTNER M; DE LUCA, GERALDINE; CASTRO RIOS M; VERRI V; VICENTE A; VARELA A; AYALA D; HELLER PG

Congreso; International Society of Thrombosis and Haemostasis ISTH 2020 virtual congress; 2020

International Society of Thrombosis and Haemostasis ISTH

Cell-free is elevated in chronic myeloproliferative neoplasms: correlation with thrombosis and disease progressionDe Luca G, Marin Oyarzún CP, Glembotsky AC, Gutierrez M, Castro Ríos M, Moiraghi B, Vicente A, Sackmann F, Bendek G, Varela A, Cortes Guerrieri Verónica, Verri Verónica, Caula Victoria, Vallejos Verónica, Lev PR, Goette NP, Ayala D, Marta RF, Schattner M, Heller PG.Background: Thrombosis remains the main complication in myeloproliferative neoplasms (MPN). Although age, previous thrombosis and JAK2V617F are associated with thrombotic risk, additional predictive factors are lacking. Cell-free(cf) DNA is associated with thrombosis in diverse prothrombotic conditions and was found elevated in small MPN cohorts. Aims:To assess whether cfDNA is useful as a biomarker for thrombosis and clinical outcome in MPN.Methods:cfDNA was measured by fluorometry using PicoGreen.Results:Circulating cfDNA was elevated in MPN (n=107) vs. controls (n=41) (P